Company Bide Pharmatech Co., Ltd.

Equities

688073

CNE100005NV3

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Bide Pharmatech Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
34.69 ^CNY	+0.84%		-4.54%	-37.50%

04-25	Bide Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	Tranche Update on Bide Pharmatech Co., Ltd.'s Equity Buyback Plan announced on December 9, 2023.	CI

Bide Pharmatech Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are the research, development, design, production and sales of drug molecular building blocks. The Company's main products are pharmaceutical molecular building blocks and scientific reagents. The Company's products are mainly used in drug target discovery, seed compound screening, lead compound discovery, synthesis and optimization. The Company conducts business in Asia Pacific, India, Europe, the United States and other regions.

Number of employees: 617

CNY in Million	2022	Weight	2023	Weight	Delta
Molecular Building Blocks Heterocyclic Compounds 43.2 %	379	45.5 %	472	43.2 %	+24.41%
Molecular Building Blocks Benzene Ring Compounds 27.1 %	219	26.3 %	296	27.1 %	+35.05%
Molecular Building Blocks Aliphatic Compounds 16.3 %	137	16.4 %	178	16.3 %	+29.86%
Catalysts and Ligands 9.7 %	77	9.2 %	106	9.7 %	+37.23%
Active Small Molecule Compounds 3.7 %	22	2.6 %	41	3.7 %	+88.42%
Other 0.0 %	0	0.0 %	0	0.0 %	+8.06%

CNY in Million	2022	Weight	2023	Weight	Delta
International 51.0 %	406	48.6 %	557	51.0 %	+37.36%
China 49.0 %	428	51.4 %	535	49.0 %	+24.88%

Managers	Title	Age	Since
Lan Dai CEO	Chief Executive Officer	52	31/03/07
Mei Cai CHM	Chairman	39	30/04/12
Rong Hao Li CTO	Chief Tech/Sci/R&D Officer	41	31/03/08
Chao Wang CTO	Chief Tech/Sci/R&D Officer	41	29/02/08
Tao Li BRD	Director/Board Member	38	31/05/19

Members of the board	Title	Age	Since
Hong Meng BRD	Director/Board Member	58	12/10/23
Tao Li BRD	Director/Board Member	38	31/05/19
Lan Dai CEO	Chief Executive Officer	52	31/03/07
Chao Wang BRD	Director/Board Member	41	28/02/18
Yun Zhao BRD	Director/Board Member	44	28/02/14
Zhi Chang Liu BRD	Director/Board Member	44	12/10/23
Yong Ping Tao BRD	Director/Board Member	61	12/10/23
Mei Cai CHM	Chairman	39	30/04/12
Rong Hao Li CTO	Chief Tech/Sci/R&D Officer	41	31/01/18
Jiang Bo Wan BRD	Director/Board Member	39	12/10/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	90,882,948	27,425,196 ( 30.18 %)	0	30.18 %

Name	Equities	%	Valuation
Lishui Xinxi Enterprise Management Partnership LP 13.41 %	5,019,806	13.41 %	24 M ¥
Lishui Landan Enterprise Management Partnership LP 11.50 %	4,305,076	11.50 %	21 M ¥
GF Fund Management Co., Ltd. 7.076 %	2,648,029	7.076 %	13 M ¥
Ningbo Dinghua Yongchuang Equity Investment Partnership LP 6.079 %	2,275,088	6.079 %	11 M ¥
Bide Pharmatech SSE STAR Strategic Placement Asset Mgmt Plan 6.071 %	2,272,074	6.071 %	11 M ¥
Gongqingcheng Nanxu Investment Partnership LP 5.298 %	1,982,851	5.298 %	10 M ¥
Aegon-Industrial Fund Management Co., Ltd. 5.163 %	1,932,057	5.163 %	9 M ¥
Shanghai Tonggao Investment Management Co. Ltd. 4.000 %	1,496,774	4.000 %	7 M ¥
Ningbo Meishan Bonded Port Area Lanyun Wanchi Invt Mgmt Pp LP 3.974 %	1,487,133	3.974 %	7 M ¥
Shanghai Changfeng Huixin Equity Investment Fund Mgmt Co. Ltd. 3.658 %	1,369,101	3.658 %	7 M ¥

Name	Equities	%	Valuation
Lan Dai 43.62 %	31,003,017	43.62 %	150 M ¥
Long Dai 18.44 %	13,106,289	18.44 %	64 M ¥

Bide Pharmatech Co., Ltd.

6/F, Building 3 999 Xiangyin Road

200433, Shanghai

http://www.bidepharmatech.com

address Bide Pharmatech Co., Ltd.(688073)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.69 CNY

Average target price

41 CNY

Spread / Average Target

+18.19%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIDE PHARMATECH CO., LTD.	-37.50%	437M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research